Psoriasis Clinical Trial

Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis

Summary

This will be an open label study of ruxolitinib topical cream applied to 2 - 20% BSA in patients with active, stable plaque psoriasis.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Subjects must have psoriatic lesions measuring protocol specific BSA

Exclusion Criteria:

Lesions solely involving the palms of the hands, the soles of the feet, the intertriginious areas, the scalp or the face
Pustular psoriasis or erythroderma

Study is for people with:

Psoriasis

Phase:

Phase 2

Estimated Enrollment:

25

Study ID:

NCT00617994

Recruitment Status:

Completed

Sponsor:

Incyte Corporation

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 4 Locations for this study

See Locations Near You


Fridley Minnesota, 55432, United States

Rochester New York, 14623, United States

Austin Texas, 78759, United States

College Station Texas, 77840, United States

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Phase:

Phase 2

Estimated Enrollment:

25

Study ID:

NCT00617994

Recruitment Status:

Completed

Sponsor:


Incyte Corporation

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider